| 去势抵抗性前列腺癌的治疗策略 |
| |
| 引用本文： | 许明伟,张杰. 去势抵抗性前列腺癌的治疗策略[J]. 世界临床药物, 2012, 33(11): 641-645 |
| |
| 作者姓名： | 许明伟 张杰 |
| |
| 作者单位： | 1.武汉大学人民医院泌尿外科,武汉,430060;2.武汉大学人民医院泌尿外科,武汉430060;湖北理工学院附属黄石中心医院,黄石435000 |
| |
| 基金项目： | 国家自然科学基金资助项目,教育部高校博士点基金资助项目 |
| |
| 摘 要： | 内分泌治疗是目前晚期前列腺癌的主要治疗方法,但大多数患者经过14～30个月的治疗后均逐渐发展为去势抵抗性前列腺癌(CRPC),其中位生存期小于20个月.相关生物靶向治疗研究较为深入,多西他赛联合泼尼松方案已成为CRPC治疗的一线化疗方案,唑来膦酸盐能明显减少骨相关事件的发生率.然而,CRPC治疗策略制定仍是目前临床的一个难题,本文结合文献报道综述CRPC的治疗策略.
|
| 关 键 词： | 去势抵抗性前列腺癌 激素难治性前列腺癌 药物治疗 |
Therapeutic strategy for castrate-resistant prostate cancer |
| |
| XU Ming-wei , ZHANG Jie. Therapeutic strategy for castrate-resistant prostate cancer[J]. WORLD CLINICAL DRUGS, 2012, 33(11): 641-645 |
| |
| Authors: | XU Ming-wei ZHANG Jie |
| |
| Affiliation: | 1,2(1.Department of Urology,Renmin Hospital of Wuhan University,Wuhan 430060,China; 2.Huangshi Central Hospital,Hubei Polytechnic University,Huangshi,435000,China) |
| |
| Abstract: | Endocrine therapy is currently the main treatment for advanced prostate cancer,but most patients gradually develop to the castrate-resistant prostate cancer（CRPC） after treatment.The median survival time of these patients is less than 20 months.Molecular targeted therapy is currently under intensive investigation for CRPC treatment.Docetaxel plus prednisone have been confirmed as the first-line medicine,and zoladronic acid has been demonstrated to be successful in reducing bone related events.However,it is still a challenge to optimize the treatment strategy for CRPC patients in the clinical.This paper reviews the progress of therapeutic strategies for CRPC patients. |
| |
| Keywords: | castrate-resistant prostate cancer hormone-refractory prostate cancer drug therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
